The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Rituximab biosimilar TRUXIMA® approved by the EMA for use in CLL and NHL
On 22nd February 2017, the European Medicines Agency (EMA) approved TRUXIMA® for use in all indications of the reference product (Roche’s MabThera®): including FL, DLBCL, and CLL.1,2
Celltrion’s TRUXIMA® is the first monoclonal antibody biosimilar that has been approved in Europe for the treatment of cancer. Mundipharma, and its network of independent associated companies, has distribution rights for 7 European countries: UK, Germany, Italy, Ireland, Belgium, Luxembourg, and the Netherlands.
TRUXIMA® is expected to be less expensive than MabThera®.1
This approval comes after the Positive Opinion given by the Committee of Medicinal Products for Human Use (CHMP), which the Lymphoma Hub reported on in January 2017.
Looking ahead, Celltrion is preparing to file TRUXIMA® in the US, selecting Teva as its commercial partner for the US and Canada.1
References